Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Completed · Phase 2

Conditions studied: Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer

In brief

The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.

Key facts

Study ID

NCT03691714

Run by

Trisha Wise-Draper

People needed

35

Starts

2018-10-23

Expected to finish

2024-12-01

Last updated by the study team

2026-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body weight > 30 kg
• Histologically or cytologically confirmed recurrent or metastatic HNSCC
• Not considered a candidate for other curative therapy (i.e. surgery/RT)
• Documented progression of disease after receiving platinum based regimen
• ECOG performance status 0-2

You may not qualify if…

• Nasopharyngeal and salivary gland tumors
• Prior exposure to both immunotherapy drugs and Cetuximab. Single exposure to either immunotherapy or cetuximab is allowed.

Where it is running

• UC Health — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.